Meg S

Marketing Manager at Decipher Urologic Cancers a subsidiary of Veracyte. My opinions are my own and not those of my employer.

[Veracyte, Inc. @Veracyte]

This weekend's #ASCO26 sessions put a spotlight on key advances in urologic cancers. Here's a recap from a session, where Christopher Sweeney, M.B.B.S., Adelaide University, presented new data from the #ENZAMET phase 3 trial.

The talk explored whether the Decipher® Prostate Genomic Classifier can identify which patients with metastatic prostate cancer may benefit from adding the chemotherapy docetaxel to androgen deprivation therapy (ADT) plus enzalutamide (also known as triplet therapy), and which may safely avoid it.

| Primary Takeaway |

🔹 The #DecipherProstateTest identifies which metastatic prostate cancer patients may benefit from treatment intensification, and which can be safely spared chemotherapy, giving clinicians an actionable, evidence-based answer.

🔹 The ENZAMET findings build on prior validation in the STAMPEDE and CHAARTED trials, where Decipher Prostate identified patients most likely to benefit from adding docetaxel to ADT alone.

🔹 ENZAMET advances that evidence with the first demonstration that the test predicts chemotherapy benefit when added to doublet therapy (ADT plus an androgen receptor pathway inhibitor, like enzalutamide).

| Some Thank You's |

💙 We're grateful to Dr. Sweeney for sharing these important findings with the oncology community and for an ongoing commitment to improving care for the millions of men living with prostate cancer worldwide, including about 30,000 in the US who present with metastatic disease at diagnosis.(1,2)

💙 Thank you to everyone who joined the session and to the investigators, site teams, and participants whose contributions made this research possible.

| Additional Resources |

Learn more about the Decipher Prostate Genomic Classifier - https://t.co/6VCW4sx9ni

ENZAMET Trial Information - https://t.co/lNVWqagngG

STAMPEDE Trial Information - https://t.co/L8BeRIGLwU

CHAARTED Trial Information - https://t.co/iLkF5W8YOM

| References |

(1) https://t.co/Q5XE5pcH6e; https://t.co/IiAknUacvv

(2) https://t.co/XdMlZgAoet

Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit: https://t.co/fQcKkGFugi
#DecipherUrologicCancers #ProstateCancer #PrecisionMedicine #ClinicalTrials #TeamVeracyte

[Veracyte, Inc. @Veracyte]

We are proud to announce the U.S. commercial launch of the Prosigna® Breast Risk of Recurrence (ROR) test, a genomic test for patients diagnosed with early-stage hormone-receptor positive (HR+) breast cancer. The #ProsignaBreastTest will be available to order starting June 8, 2026.

| Impact |

On the heels of the landmark #OPTIMA trial readout at #ASCO26, the Prosigna test now offers clinicians and the patients they serve not only a deeper understanding of individual risk of recurrence, but for many, whether chemotherapy can benefit them or whether they may safely avoid it.

In the U.S., more than 225,000 new HR+/HER2- breast cancer cases are diagnosed each year. When breast cancer is diagnosed early and treated appropriately, five-year survival rates reach 92%(1). It is critically important to accurately determine a patient's risk of recurrence because the effects of treatment escalation or de-escalation have a lasting impact on a patient's life.

| Why the Prosigna Test Stands Apart |

🔹 Comprehensive molecular analysis: The Prosigna test was developed from the PAM50 genomic classifier and is the only test that combines intrinsic subtypes and proliferation score with clinical pathological factors to provide a comprehensive 10-year probability of distant recurrence.

🔹 Proven across high-risk populations: Based on the phase III, prospective, OPTIMA trial, the Prosigna test is the only test proven to be predictive for chemotherapy benefit for high-clinical risk patients with up to 9 positive nodes, including premenopausal women treated with ovarian function suppression.

🔹 Superior prognostic accuracy: Extensively validated clinical evidence demonstrates that the Prosigna test is more prognostically accurate than other genomic assays, particularly in the critical 5-10 year breast cancer recurrence window.

| Access and Availability |

The Prosigna test will be available to order starting June 8, 2026 through Veracyte's network nationwide via the Veracyte Ordering Portal. The test is currently covered by most commercial payers, and patients may qualify for financial assistance or a tailored payment plan supported by the Veracyte Access Program for eligible uninsured and underinsured patients.

| Resources |

📄 Read the full press release - https://t.co/B8LeuqFGKd

🔗 Prosigna clinical resources - https://t.co/vGSwkG60Z9

🔗 Veracyte ordering portal for providers - https://t.co/tdzUPwYmwK

#BreastCancer #PrecisionMedicine #CancerDiagnostics

| References |

(1) National Breast Cancer Foundation, Inc., Breast Cancer Facts & Stats; Last updated Apr 20, 2026. https://t.co/ZmPKXGmCFp

Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit: https://t.co/fQcKkGFugi

[Veracyte, Inc. @Veracyte]

Veracyte is proud to announce new findings from an analysis of patient samples from the ENZAMET trial, an international, randomized Phase III study conducted by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).

The analysis demonstrates that the Decipher® Prostate test identifies which men with metastatic prostate cancer may benefit from adding the chemotherapy docetaxel to standard hormonal therapy (also known as triplet therapy), and who may safely avoid it, providing the first Level 1B evidence for a genomic test guiding this decision.

| Key Findings |

The new ENZAMET trial results provide evidence for genomic-guided decisions on triplet therapy in advanced disease:

🔹Improved outcomes guided by Decipher Prostate: Patients with higher Decipher scores (>0.85) who received triplet therapy had clinically meaningful better survival compared to those on standard hormonal therapy alone.

🔹Patients can be spared from chemotherapy: Patients with lower Decipher scores showed no benefit from adding chemotherapy, suggesting it may be safely avoided.

🔹 Overcoming aggressive disease: Patients with higher Decipher scores who received triplet therapy had more aggressive disease features, yet achieved comparable survival to lower-risk patients on doublet therapy, suggesting chemotherapy offset the poor prognostic effects of aggressive disease biology.

Prof. Christopher Sweeney, MBBS, South Australian Immunogenomics Cancer Institute, Adelaide University, will present the ENZAMET trial results at the #ASCO26 Annual Meeting.

| Presentation Details |

📅 Date: Saturday, May 30 ⏰ Time: 1:15 PM CDT

📍 Location: Prostate, Testicular, and Penile, Hall D1, Abstract 5001

| Resources |

🤝 Visit Booth 13069: Stop by to connect with #TeamVeracyte and learn how the Decipher Prostate Genomic Classifier test can assess risk of metastasis or metastatic progression in patients with localized or advanced prostate cancer.

🔗 Event information - https://t.co/ctQ66JYGC8

📄 Read full press release - https://t.co/jkoowOJJL5

🧬 More on the ENZAMET trial - https://t.co/lNVWqagngG
#DecipherUrologicCancers #ProstateCancer #PrecisionMedicine #ClinicalTrials #CancerDiagnostics

Note: This article contains forward-looking statements, which involve risks and uncertainties. For more information visit - https://t.co/fQcKkGFugi

[Veracyte, Inc. @Veracyte]

🚨Happening this afternoon! 🚨

🎤  Hear the Latest Findings from the ENZAMET Phase 3 Trial

Christopher Sweeney, MBBS, South Australian Immunogenomics Cancer Institute, Adelaide University, will share the first look at new results from the ENZAMET trial, which assesses whether the Decipher® Prostate Genomic Classifier can predict benefit from adding chemotherapy to androgen deprivation therapy plus enzalutamide) for men with metastatic hormone sensitive prostate cancer.

| Session Details |

Session: Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ): Level 1B evidence from the ENZAMET study

📅 Date / Time: Saturday, May 30, 2026, 3:12 PM CT

📍 Location: Genitourinary Cancer—Prostate, Testicular, and Penile, Hall D1, Abstract 5001

#ProstateCancer #ClinicalTrials #ClinicalResearch #PrecisionMedicine #CancerDiagnostics #OncologyResearch #DecipherUrologicCancers

[Veracyte, Inc. @Veracyte]

We are excited to announce that more than 15 abstracts featuring our urology portfolio will be presented this week at the 2026 ASCO Genitourinary Cancers Symposium (#ASCOGU). The abstracts span studies across prostate and bladder cancers, featuring:

🔹 Real-world data for Decipher Prostate

🔹 New insights from phase II clinical trials, including one utilizing our upcoming TrueMRD Muscle-Invasive Bladder Cancer (MIBC) test

“The breadth of data at ASCO GU shows how our Veracyte Diagnostics Platform is driving meaningful insight across multiple urologic cancers,” said Elai Davicioni, Ph.D., Veracyte’s medical director, Urology.

Read press release - https://t.co/mKpZnkoRzz

#Decipher #TrueMRD #MRD #ASCOGU2026 #CancerDiagnostics #UrologicCancer #PrecisionMedicine

[Decipher by Veracyte @Decipher_VCYT]

This September, @Veracyte's Decipher team proudly joins patients and organizations worldwide in recognizing #ProstateCancerAwarenessMonth. We wear blue to show our unwavering support. #ProstateCancerAwarenessMonth

[Veracyte, Inc. @Veracyte]

In celebration of #IWD, Veracyte Women's Leadership hosted a fireside chat with Ryen MacDonald and Katrina Nashashibi, where they discussed career growth, persevering through challenges, mentorship, and much more. Thank you Ryen, Katrina, & the VWL team for this inspiring event!

[Veracyte, Inc. @Veracyte]

Veracyte today announced that it’s Decipher Prostate Genomic Classifier is the only gene expression test to receive a “Level 1B” evidence rating in the 2024 @NCCN Guidelines® as a prognostic tool for the risk stratification of patients with localized #ProstateCancer.

[Meg S @meg17_s]

@erastourticks It’s via DailyMail https://t.co/bYJhML4hXZ

[Zach Klaassen @zklaassen_md]

Cross-Comparison IPD Analysis of Three Gene Expression Signatures in Localized #prostatecancer in >50,000 Men #ASTRO23 @a@angela_jia_ @urotoday

📌 15,379 NCCN low-risk, 14,773 fav int-risk, 15,544 unfav int-risk, and 5,185 high/very high-risk
📌 Oncotype model had poor goodness-of-fit to the 22-gene Decipher GC: R2 = 0.36
📌 Prolaris model had poor goodness-of-fit to the 22-gene Decipher GC: R2 = 0.32
📌 ~60% of information from the Decipher GC is unique and not explained by known variables
📌 These tests should not be viewed as interchangeable

[Daniel E Spratt @DrSpratticus]

@angela_jia_ giving a podium talk @ASTRO_org #ASTRO23 and absolutely crushing it.

The gene expression used in the 3 most common PCa tests in 50,000 pts do not correlate, with ~60% of data being unique in Decipher as compared to derived CCP or GPS.

Clearly these tests are not interchangeable in the info provided.

#radonc #PCSM @urotoday @PCFnews @RadOncUH

[Veracyte, Inc. @Veracyte]

Members from our SD office were excited to participate in the San Diego Zero Prostate 5K Run & Walk earlier this month! Thanks to all who donated & joined this important event supporting #ProstateCancer patients – we were honored to be recognized as the largest team. #ZEROStrong

[Veracyte, Inc. @Veracyte]

New data from studies encompassing over 100,000 #ProstateCancer patients were presented at #AUA23, reinforcing the clinical utility of Veracyte's Decipher Prostate test and its role as a new standard of care to help inform treatment decisions for these patients.

[Decipher by Veracyte @Decipher_VCYT]

If you're attending #AUA23 here in Chicago, be sure to check out these eight posters featuring @Veracyte's #Decipher tests!

[Decipher by Veracyte @Decipher_VCYT]

Veracyte's Decipher team is in Chicago, exhibiting at the American Urological Associations 2023 (#AUA23) meeting taking place April 28 - May 1! If you're attending, visit booth #637 to hear about some of our latest research efforts to help patients with #ProstateCancer.

[Decipher by Veracyte @Decipher_VCYT]

ICYMI: Decipher Prostate helps provide clarity and confidence to #ProstateCancer treatment planning. This video from PRIMR helps explain @Veracyte's Decipher Prostate test to patients, including how it can help physicians make more-informed decisions for their patients. #genomics

[Decipher by Veracyte @Decipher_VCYT]

Today, March 30th, in honor of National Doctors' Day, we want to take a moment to recognize the physicians who have helped save the lives of patients living with #ProstateCancer and #BladderCancer. Thank you for all you do!

[Decipher by Veracyte @Decipher_VCYT]

@Veracyte’s Decipher team at the 2023 ASCO Genitourinary Cancers Symposium last week.

Thank you to those who stopped by to discuss the latest #Decipher data! #GU23 @ASCO

[Decipher by Veracyte @Decipher_VCYT]

The 28th Annual Paul C. Peters Urology Symposium starts tomorrow in Irving, Texas! Stop by our booth between February 2-4 to learn how
@Veracyte's #Decipher Prostate Genomic Classifier can help personalize #ProstateCancer treatment planning. #PaulPeters

[Decipher by Veracyte @Decipher_VCYT]

As we welcome 2023, we would like to thank our customers and amazing team for an incredible 2022. We appreciate all that you do and wish you a healthy and Happy New Year!